B+
Bull case
0%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
SDGR
SchrodingerFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
ACV growth, Bunsen adoption, the BMS deployment, and collaboration economics could improve long-term platform utilization. The $418.8 million cash, cash equivalents, restricted cash, and marketable securities balance provides flexibility.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Bunsen adoption, pricing, and contribution to ACV remain unproven.
Momentum
95
Value
36
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $22.00 · Bear $14.00Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $25.86
Why
Momentum95 · Δ7d -2.2
Value36 · Δ7d +0.0
Sentiment32 · Δ7d -3.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Bunsen adoption, pricing, and contribution to ACV remain unproven.
- • Drug-discovery revenue depends on collaboration milestones and partner execution.
- • The quarter included a $48.9 million other-income benefit largely tied to the Ajax acquisition, while software revenue declined and Bunsen monetization is not yet demonstrated.
Catalyst clock
2026-08-05
Q2 ACV growth and higher drug-discovery guidance
Lead driver: Value · See fundamentals
Momentum
95
8% active weight
Current posture
7d trendImproving
Δ7d
-2.2
Δ21d
-3.0
Value
36
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
32
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.9
Δ21d
+16.2
Why this grade
Composite grade F. Momentum 94.8 / Value 36.3 / Sentiment 32.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.78B
Beta
1.58
Shares Out
74.81M
P/E (TTM) · Derived
-16.9
P/S (TTM)
5.30
P/FCF (TTM)
22.41
Rev YoY
+7.5%
EPS YoY
-113.4%
Gross Margin
+56.9%
Op Margin
-59.2%
Net Debt
-$293.1M
Current Ratio
2.71
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data